Evidence Repository - Clinical Genome Resources

The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Variant: NM_001754.5(RUNX1):c.1159_1161del (p.Gly387del)

Curation Version - 1.0
Curation History
JSON LD for Version 1.0

CA16616514

409819 (ClinVar)

Gene: RUNX1

Condition: hereditary thrombocytopenia and hematologic cancer predisposition syndrome

Inheritance Mode: Autosomal dominant inheritance

Link to MONDO

UUID: 78031b2f-32da-4fd9-a089-e6bc33bfd63a

Approved on: 2024-08-01

Published on: 2024-08-01

HGVS expressions

NM_001754.5:c.1159_1161del

NM_001754.5(RUNX1):c.1159_1161del (p.Gly387del)

NC_000021.9:g.34792418_34792420del

CM000683.2:g.34792418_34792420del

NC_000021.8:g.36164715_36164717del

CM000683.1:g.36164715_36164717del

NC_000021.7:g.35086585_35086587del

NG_011402.2:g.1197293_1197295del

ENST00000675419.1:c.1159_1161del

ENST00000300305.7:c.1159_1161del

ENST00000344691.8:c.1078_1080del

ENST00000399240.5:c.886_888del

ENST00000437180.5:c.1159_1161del

ENST00000482318.5:c.*749_*751del

NM_001001890.2:c.1078_1080del

NM_001754.4:c.1159_1161del

NM_001001890.3:c.1078_1080del

Uncertain Significance

PM2_Supporting

BS2 BS1 BS4 BS3 BP4 BP3 BP1 BP2 BP5 BP7 BA1 PS1 PS2 PS3 PS4 PP1 PP2 PP3 PP4 PVS1 PM6 PM1 PM3 PM5 PM4

Evidence Links 0

Expert Panel

Myeloid Malignancy VCEP

Criteria Specification Information

Criteria Specification: ClinGen Myeloid Malignancy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 2

PDF

Criteria Specification Approval History

Criteria Specifications for this VCEP

Evidence submitted by expert panel

Myeloid Malignancy VCEP

NM_001754.5(RUNX1):c.1159_1161del (p.Gly387del) is an in-frame deletion which does not affect any residues within the Runt Homology Domain (AA 89-204) (PM4 not applied). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_Supporting). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PM2_supporting.

PM2_Supporting

This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_Supporting).

BS2

This rule is not applicable for MM-VCEP

BS1

This variant does not have a MAF between 0.00015 (0.015%) and 0.0015 (0.15%) in any general continental dataset.

BS4

No case studies found

BS3

No functional studies found

BP4

No missense, synonymous, or intronic variant

BP3

This rule is not applicable for MM-VCEP

BP1

This rule is not applicable for MM-VCEP

BP2

No homozygotes present in gnomAD v3.1.2.

BP5

This rule is not applicable for MM-VCEP

BP7

Not a synonymous or intronic variant

BA1

This variant does not have a MAF ≥ 0.0015 (0.15%) in any general continental population dataset.

PS1

This variant is not a missense variant.

PS2

No case studies found

PS3

No functional studies found

PS4

No case studies found

PP1

No case studies found

PP2

This rule is not applicable for MM-VCEP

PP3

No missense, synonymous, or intronic variant

PP4

This rule is not applicable for MM-VCEP

PVS1

This variant is not a null variant.

PM6

No case studies found

PM1

Not a missense variant

PM3

This rule is not applicable for MM-VCEP

PM5

This variant is not a missense variant.

PM4

This in-frame deletion/insertion does not affect any of the following amino acid residues, nor is it located within the RHD: R107, K110, A134, R162, R166, S167, R169, G170, K194, T196, D198, R201, R204 OR within residues 89-204.

Curation History

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.